Compare Stocks

→ A new way to collect income from stocks (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKUS Akouos	$13.29	$13.29	$2.32 ▼ $13.60	$490.88M	-0.55	344,411 shs	440 shs
FBRX Forte Biosciences	$0.71 -4.1%	$0.70	$0.38 ▼ $1.15	$26.88M	0.48	26,555 shs	14,300 shs
GERN Geron	$3.58 +2.3%	$2.80	$1.64 ▼ $4.05	$1.91B	0.62	9.96 million shs	6.62 million shs
PRVB Provention Bio	$24.98 +3.1%	$24.58	$3.18 ▼ $25.00	$2.37B	2.47	2.28 million shs	9.12 million shs
WIZP Mawson Infrastructure Group	$1.34 -11.3%	$1.45	$0.07 ▼ $1.45	$651.67M	1.77	141,517 shs	375,161 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKUS Akouos	0.00%	0.00%	0.00%	0.00%	0.00%
FBRX Forte Biosciences	-3.87%	-4.05%	0.00%	+3.59%	-32.38%
GERN Geron	+2.29%	-2.72%	+9.82%	+65.74%	+47.93%
PRVB Provention Bio	0.00%	0.00%	0.00%	0.00%	+3.10%
WIZP Mawson Infrastructure Group	-3.82%	+46.60%	-4.43%	-28.44%	-50.00%

Did You Get Your Free Bitcoin Yet? (Ad)

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKUS Akouos	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	3.2963 of 5 stars	3.3	5.0	0.0	0.0	2.2	2.5	1.3
GERN Geron	3.2734 of 5 stars	3.5	3.0	0.0	1.3	1.4	1.7	0.6
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
WIZP Mawson Infrastructure Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKUS Akouos	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	2.50	Moderate Buy	$2.75	287.32% Upside
GERN Geron	3.00	Buy	$5.33	48.98% Upside
PRVB Provention Bio	N/A	N/A	N/A	N/A
WIZP Mawson Infrastructure Group	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest FBRX, GERN, PRVB, AKUS, and WIZP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
4/10/2024	GERN Geron	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$6.00
4/8/2024	FBRX Forte Biosciences	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$2.75
3/15/2024	GERN Geron	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$6.00
3/15/2024	GERN Geron	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
3/15/2024	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
2/28/2024	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKUS Akouos	N/A	N/A	N/A	N/A	$4.90 per share	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$0.97 per share	N/A
GERN Geron	$240K	8,157.48	N/A	N/A	$0.46 per share	7.78
PRVB Provention Bio	$12.90M	183.54	N/A	N/A	$1.40 per share	17.84
WIZP Mawson Infrastructure Group	N/A	N/A	N/A	N/A	$0.03 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKUS Akouos	-$86.67M	-$2.62	N/A	N/A	N/A	N/A	-45.09%	-36.86%	N/A
FBRX Forte Biosciences	-$31.48M	-$1.04	N/A	N/A	N/A	N/A	-94.27%	-81.36%	5/20/2024 (Estimated)
GERN Geron	-$184.13M	-$0.33	N/A	N/A	N/A	-77,691.14%	-63.33%	-44.71%	5/9/2024 (Estimated)
PRVB Provention Bio	-$113.57M	-$1.53	N/A	N/A	N/A	-880.69%	-103.36%	-69.08%	N/A
WIZP Mawson Infrastructure Group	-$3.45M	-$0.33	N/A	N/A	N/A	N/A	N/A	-85.32%	N/A

Latest FBRX, GERN, PRVB, AKUS, and WIZP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/18/2024	Q4 2023	FBRX Forte Biosciences	N/A	-$0.04	-$0.04	-$0.04	N/A	N/A
2/28/2024	Q4 23	GERN Geron	-$0.10	-$0.09	+$0.01	-$0.09	$0.06 million	$0.02 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKUS Akouos	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A
WIZP Mawson Infrastructure Group	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKUS Akouos	N/A	17.30	17.30
FBRX Forte Biosciences	N/A	10.45	10.45
GERN Geron	0.14	3.16	3.16
PRVB Provention Bio	0.19	1.93	1.92
WIZP Mawson Infrastructure Group	N/A	1.13	1.13

Ownership

Institutional Ownership

Company	Institutional Ownership
AKUS Akouos	N/A
FBRX Forte Biosciences	77.63%
GERN Geron	73.71%
PRVB Provention Bio	37.39%
WIZP Mawson Infrastructure Group	N/A

Insider Ownership

Company	Insider Ownership
AKUS Akouos	4.80%
FBRX Forte Biosciences	10.53%
GERN Geron	3.10%
PRVB Provention Bio	13.10%
WIZP Mawson Infrastructure Group	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AKUS Akouos	103	36.94 million	35.16 million	Not Optionable
FBRX Forte Biosciences	9	36.40 million	32.56 million	Optionable
GERN Geron	141	546.87 million	529.92 million	Optionable
PRVB Provention Bio	82	94.78 million	82.37 million	Not Optionable
WIZP Mawson Infrastructure Group	2	486.32 million	N/A	Not Optionable

FBRX, GERN, PRVB, AKUS, and WIZP Headlines

Source	Headline
	Mawson Infrastructure Group adds new customer at Midland bitcoin facility bizjournals.com - December 20 at 11:39 AM
	Mawson announces agreement for half of Midland bitcoin facility capacity bizjournals.com - October 19 at 5:32 PM
	Mawson Infrastructure reports BTC production of 69 in July, down 3% M/M seekingalpha.com - August 24 at 6:28 PM
	H.C. Wainwright Sticks to Its Buy Rating for Mawson Infrastructure Group (MIGI) markets.businessinsider.com - August 24 at 7:44 AM
	Mawson Infrastructure Group Inc. Invites Submission of Indication of Interest for its BTC Hosting and HPC Co-location Services technews.tmcnet.com - July 25 at 10:20 AM
	Mawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2023 businesswire.com - July 19 at 10:01 AM
	Mawson Infrastructure Group Inc. Announces Monthly Operational Update for May 2023 technews.tmcnet.com - June 14 at 10:10 AM
	Mawson Infrastructure Group names new president, CEO bizjournals.com - May 22 at 12:56 PM
	With Significant Increases In Megawatt Capacity And Bitcoin Production, Mawson Infrastructure Group (NASDAQ: MIGI) May Attract More Bitcoin Mining Investors msn.com - April 11 at 10:13 AM
	Earnings Outlook For Mawson Infrastructure msn.com - November 12 at 8:40 PM
	Bitcoin Miner CleanSpark Buys Mawson Site as Consolidation Rises finance.yahoo.com - September 11 at 12:26 AM
	Mawson Infrastructure Group Inc. To Sell Sandersville, Georgia Bitcoin Mining Facility including 6468 ASIC Bitcoin Miners To CleanSpark, Inc. For Up To $42.5 Million benzinga.com - September 9 at 10:20 AM
	Why Bitcoin- And Ethereum-Related Stock CleanSpark Is Rising Today benzinga.com - September 9 at 10:20 AM
	Mawson Infrastructure Group Inc. Announces July 2022 Bitcoin Self-Mining, Hosting Co-location, Energy Demand Response and Operational Update finance.yahoo.com - August 25 at 10:24 AM
	Mawson Infrastructure Group Inc. Schedules Second Quarter Results Webcast for 5:30 p.m. ET on August 22, 2022 benzinga.com - August 18 at 9:55 AM
	Bitcoin Miner Mawson Infrastructure Produced 185 Bitcoin In Record-Breaking May bitcoinmagazine.com - June 16 at 3:23 PM
	Mawson to Develop New Bitcoin Mining Site in Texas finance.yahoo.com - May 17 at 2:50 AM
	Mawson Infrastructure Group Inc. Announces New 120 Megawatt Bitcoin Mining Facility in Texas, USA tmcnet.com - May 16 at 9:34 AM
	Texas Pacific Land Corporation, Mawson Infrastructure Group Inc., and JAI Energy Announce New Bitcoin Mining Venture in West Texas tmcnet.com - May 16 at 9:34 AM
	Mawson Infrastructure Group discusses Q3 highlights including Quinbrook renewable energy partnership proactiveinvestors.com - December 14 at 11:45 PM
	Audacious Secures $20M Funding & Closes $3.1M Non-Brokered Private Placement Tranche benzinga.com - December 11 at 11:01 PM
	Essential Investment? This REIT Believes in Cannabis-Related Real Estate benzinga.com - December 9 at 6:25 PM
	South Dakota's Supreme Strikes Down Recreational Cannabis Vote, Overturning People's Will benzinga.com - November 28 at 6:55 PM
	10 Weed Strains For People Who Like Cheese benzinga.com - November 8 at 12:11 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akouos

NASDAQ:AKUS

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Forte Biosciences

NASDAQ:FBRX

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Geron

NASDAQ:GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Provention Bio

NASDAQ:PRVB

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Mawson Infrastructure Group

OTCMKTS:WIZP

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial